The primary focus of this study was to know whether labeling nanoparticles with a cancer cell specific aptamer could enhance selective delivery of siRNA into tumor cells leading to enhanced knock-down of P-glycoprotein or P-gp as compared to non-labeled nanoparticles. Here, ABCB1 is linked to cancer.